Patents
Literature
78 results about "Isotype" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In immunology, the immunoglobulin (Ig) isotype (class) is encoded by the constant region segments of the immunoglobulin gene which form the Fc (Fragment crystallizable region) portion and the lower segment of the Fab (Fragment antigen-binding) portion of an antibody. The expression of a specific isotype determines the function of an antibody via the specific binding to Fc receptor molecules on different immune effector cells. Isotype expression reflects the maturation stage of a B cell. Naive B cells express IgM and IgD isotypes with unmutated variable genes, which are produced from the same initial transcript following alternative splicing. Expression of other antibody isotypes (IgD, IgM IgG1-4, IgA1-2, IgE) occurs via a process of class-switch recombination (CSR) after antigen exposure. Class-switching is mediated by the AID (activation-induced cytidine deaminase) enzyme and only occurs after the B cell binds an antigen through its B cell receptor, and is further activated through interaction with a T helper cell.
Systems and methods for generating multivalent mosaic HLA nanoparticles for personalized immunotherapy applications
PCT designated stage expiredWO2025049742A1Cell receptors/surface-antigens/surface-determinantsDepsipeptidesNanoparticleAllotype
Owner:THE CHILDRENS HOSPITAL OF PHILADELPHIA
Systems and methods for assessment of immune response and applications thereof
PCT designated stageWO2025175065A1Immunoglobulin superfamilyMedical data miningImmune receptorImmunity response
Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Chimeric antigen receptors against multiple HLA-g isoforms
PendingUS20260070988A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyWhite blood cellAntigen receptors
The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G β2M-free or β2M-associated immunosuppressive isoforms respectively.
Owner:INVECTYS SA
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using Anti-ROR1 antibody conjugates
PendingUS20250135025A1Organic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesAntibody conjugate
The present disclosure relates to antibodies and antibody conjugates, for instance antibody drug conjugates, with binding specificity for receptor tyrosine kinase orphan receptor 1 (ROR1) and its isoforms and homologs, and compositions comprising the antibodies or antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibodies and antibody conjugates and compositions thereof as well as methods of using the antibodies and antibody conjugates and compositions thereof, such as in therapeutic and diagnostic methods.
Owner:SUTRO BIOPHARMA INC
Anti-death receptor antibodies and methods of use thereof
The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.
Owner:GENMAB BV
Hepatocyte nuclear factor four alpha antisense RNA 1 targeting polynucleotide and method of use and treatment thereof
The present invention comprises a pharmaceutic composition comprising one or more hepatocyte nuclear factor four alpha antisense RNA 1 (HNF4A-AS1) targeting polynucleotides, wherein the one or more HNF4A-AS1 targeting polynucleotides is capable of repressing HNF4A-AS1 in a subject resulting in upregulation of HNF4A expression and / or increasing HNF4A P1:P2 isoform ratio in the subject. The present invention also provides a method of treatment of a HNF4A-associated disease in a subject comprising the step of administering a therapeutically effective amount of the pharmaceutical composition comprising one or more HNF4A- AS1 targeting polynucleotides of the present invention. The present invention also provides a method of downregulating HNF4A P2 isoform expression in a subject comprising the step of repressing HNF4A-AS1 in the subject.
Owner:GENECO PTY LTD
Composition comprising an IgE antibody
ActiveUS12606617B2Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsPharmacy medicineIntravenous gammaglobulin
In one aspect, the present invention relates to a pharmaceutical unit dosage composition comprising an antibody of isotype immunoglobulin E (IgE), wherein the composition comprises less than 50 mg of the IgE antibody. The pharmaceutical unit dosage compositions may be administered to a mammalian subject and find use in treating cancer, in particular, human ovarian cancers.
Owner:KINGS COLLEGE LONDON
MASP isotypes as inhibitors of complement activation
This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.
Owner:OMEROS CORP
Natural killer cell cement
PendingCN120787237AAntibody mimetics/scaffoldsPeptide/protein ingredientsCancer cellNatural Killer Cell Inhibitory Receptors
The invention relates to methods and materials for treating cancer. For example, provided herein are cell adhesives capable of binding to natural killer (NK) cells and cancer cells. In some cases, the cell binding agents provided herein may comprise a first antigen binding domain capable of binding to a NK cell group 2 isoform C (NKG2C) polypeptide and a second antigen binding domain capable of binding to a cancer cell surface polypeptide. In some cases, one or more cell binding agents provided herein may be administered to a mammal (e.g., a human) having a cancer (e.g., a leukemia such as acute myelogenous leukemia (AML)) to treat cancer.
Owner:REGENTS OF THE UNIVERSITY OF MINNESOTA +1
Targeting mutant KRAS with a mutation specific iga
Disclosed herein are dimeric or pentameric antigen binding molecules and methods for making said dimeric or pentameric antigen binding molecules, wherein the isotype of the immunoglobulin monomers is IgA, 1gG4, or IgM. Also disclosed herein are methods of using dimeric antigen binding molecules to treat cancer associated with expression of an oncogene, gene overexpression, or a gene fusion.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC
Bispecific antibodies and constructs for lysosomal targeting degradation and methods of use thereof
PendingUS20260055194A1Immunoglobulins against cell receptors/antigens/surface-determinantsLysosomal targetingBispecific antibody
Provided herein are antigen-binding proteins (ABPs) that selectively bind to M6PR and its isoforms and homologs, and compositions comprising the ABPs. Also provided herein are bispecific antigen-binding proteins (ABPs) that selectively bind to internalizing receptors, and a soluble target molecule or cell surface target molecule and its isoforms and homologs, and compositions comprising the ABPs.
Owner:LYCIA THERAPEUTICS INC
P53 isoform variant for diagnosing cancer
PendingUS20260092923A1Immunoglobulins against animals/humansDisease diagnosisAntiendomysial antibodiesDeletion mutation
A method of collecting data for diagnosing cancer, determining an onset risk, determining a malignancy grade, and / or predicting a prognosis of cancer according to the present disclosure includes the steps of bringing a sample derived from a subject into contact with tumor-associated antigens to cause an antigen-antibody reaction; measuring an amount of anti-p53 antibody, in the sample, that specifically binds to any of the tumor-associated antigens; and comparing the measured amount of the anti-p53 antibody with a predetermined reference level of the anti-p53 antibody against the tumor-associated antigens. The tumor-associated antigens include one or more p53 isoform variants consisting of amino acid sequences having a mutation in an amino acid sequence of any one of SEQ ID NOs: 1 to 3, and the mutation includes any one of an N-terminal deletion mutation, a C-terminal deletion mutation, and both the N-terminal deletion and the C-terminal deletion mutation.
Owner:TUNING FORK BIO INC
CNOT9 binding RNA degraders
The present invention includes compounds and compositions, and methods of use thereof for modulating an RNA transcript, or a precursor, isoform, fragment, or mutant thereof by degradation of the RNA transcript via recruitment or binding of one or more decay factors (e.g., an RNA binding protein).
Owner:ARRAKIS THERAPEUTICS INC
ANTIBODIES SELECTIVE TO 4Ig ISOFORM OF B7-H3 AND METHODS OF USE THEREOF
PendingCN120787161APolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen bindingInflammation
Provided herein are antibodies and antigen-binding portions thereof that specifically bind to the 4Ig isoform of B7 homolog 3 protein (B7-H3), various compositions of such antibodies or antigen-binding portions thereof, and recombinant nucleic acids encoding the antibodies and antigen-binding portions thereof. Also provided are methods of using the antibodies or antigen-binding portions thereof in the treatment and diagnosis of cancer or inflammation.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
PCT designated stageWO2026035843A3Genetically modified cellsImmunoglobulins against virusesImmunoglobulin heavy chainHuman cell
Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC
Anti-HLA-dr igm isotype monoclonal antibody potentiating the activity of Anti-CD20 igg1 or igm isotype antibodies
PCT designated stageWO2025253079A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesMalignancy
The present invention relates to a novel anti-HLA-DR IgM isotype monoclonal antibody and to the use thereof alone or in addition to anti-CD20 IgG1 or IgM isotype antibodies, in the treatment of B-phenotype lymphoid hemopathies, and in particular of non-Hodgkin lymphoma B, chronic lymphocytic leukemia (CLL) and B-cell malignant lymphoid hemopathies in general.
Owner:CENT NAT DE LA RECH SCI (C N R S) +5
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
PendingUS20260123608A1Genetically modified cellsImmunoglobulins against virusesImmunoglobulin heavy chainConstant region
Non-human animals (and / or non-human cells) and methods of using the same are provided, which non-human animals (and / or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that are of IgA, IgD, or IgM isotypes. Non-human animals provided herein are, in some embodiments, characterized by expression of IgA antibodies that contain human heavy chain and light chain variable domains and rodent constant domains. Methods for producing antibodies from non-human animals are also provided, which antibodies contain human variable regions and rodent constant regions.
Owner:REGENERON PHARMACEUTICALS INC
Tumor-selective e1a and e1b mutants
Modified E1a regulatory sequences are provided, wherein at least one Pea3 binding site, or a functional portion thereof, is deleted. Also provided are modified E1a sequences that selectively express particular isoforms. Also provided is an E1b-19K clone insertion site. These modified sequences can be used individually, or in combination with one another, to provide tumor-selective expression of proteins.
Owner:RGT UNIV OF CALIFORNIA
Method for in-vivo detection of tumor cell killing effect of NK cells
PendingCN119970797AMammal material medical ingredientsIndividual particle analysisHuman tumorNatural Killer Cell Inhibitory Receptors
The invention relates to the technical field of tumor cell killing, in particular to a method for in-vivo detection of the tumor cell killing effect of NK cells, and the method comprises the following steps: S1, taking killing of male C57BL / 6 mouse NK cells on Hela cells and other types of human-derived tumor cells under in-vivo conditions as a model, and taking the Hela cells as a contrast; s2, grouping the selected mice, and correspondingly performing intraperitoneal injection of isotype IgG, an anti-NK1.1 antibody and an anti-mouse NKG2D monoclonal antibody; s3, preparing a cell mixed solution of to-be-detected tumor cells and Hela cells; s4, injecting the cell mixed liquid into the body of the mouse in a caudal vein injection manner; s5, killing each group of mice, and taking lungs to prepare a single-cell suspension; s6, detecting the number of CFSE positive cells and the number of PKH26 positive cells in the mouse lung single-cell suspension by adopting a flow cytometer; and S7, calculating the survival rate of the tumor cells to be detected. The method well solves the problem that the killing effect of the NK cells on the human tumor cells is difficult to accurately and truly evaluate in the prior art.
Owner:ZHEJIANG MEDICAL COLLEGE
Soluble interleukin-7 receptor (sIL7R) modulation therapy for the treatment of autoimmune diseases and cancer
The present invention includes compositions and methods for treating autoimmune diseases or cancers in a subject in need thereof, the methods comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds to a complementary sequence of interleukin-7 receptor (IL7R) pre-mRNA that affects exon 6 splicing, wherein the SM-ASO increases or decreases the inclusion of exon 6 in the IL7R pre-mRNA and respectively decreases or increases the expression of the soluble isoform (sIL7R) of IL7R. In some embodiments, the oligonucleotide is an antisense oligonucleotide (ASO) or a splicing-modulating antisense oligonucleotide (SM-ASO).
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Sirna for silencing a new isoform of the mitochondrial chaperone trap1
A siRNA characterised by having a sequence selected from the group comprised of: - SEQ ID NO. 1 : 5 ' CUCUUUCCCUUGAAUAAGC 3 '; - SEQ ID NO. 2 : 5 ' UGAUUCCCAAAGCUCACAG 3 '; and - a sequence including at least 16 contiguous nucleotides differing by no more than 3 nucleotides from SEQ ID No. 1 or SEQ ID No. 2, to silence TRAPl-low SEQ ID N°3. The use of the 5 'UTR SEQ ID N°4 region of the TRAPl-low transcript SEQ ID N°3 or a portion of that 5 'UTR region selected from the group comprised of: - the SEQ ID No. 6 portion of said 5 ' UTR region comprising nucleotide positions 1 through 644; - a portion of said region 5 ' UTR comprising the portion of SEQ ID No. 6 extended by a predetermined number of nucleotide positions beyond nucleotide position 644 along said region 5 'UTR.
Owner:C R O B CENT DI RIFERIMENTO ONCOLOGICO DELLA BASILICATA INST DI RICOVERO E CURA A CARATTERE SCIO +1
Compositions and methods for immune cell modulation in adoptive cell therapy
PendingUS20260034216A1Polypeptide with localisation/targeting motifImmunoglobulin superfamilyAdoptive cellular therapyWhite blood cell
The disclosure relates to adoptive cell therapy compositions including a population of isolated immune cells that are obtained from a donor subject. The immune cells can be modified to suppress Bruton's tyrosine kinase (BTK), interleukin-2-inducible T cell kinase (ITK), delta isoform of phosphoinositide 3-kinase (PI3Kδ), helios, blimp1, SOCS1, GATA3, IL-10, STAT3, TOX, CD25, foxp3, Ezh2, TGF-beta Receptor II, LAG-3, PD-1, TNF-alpha, or combinations thereof. The immune cells are optionally depleted of CD8+ T cells by about 10-fold or greater relative to un-depleted leukocytes.
Owner:JOHNS HOPKINS UNIVERSITY +1
New splice variant isoform of VEGF
PendingUS20250346642A1Peptide/protein ingredientsMicrobiological testing/measurementLymphatic vesselLymphangiogenesis
The present invention relates notably to a new isolated splice variant isoform of VEGF having pro-angiogenic and pro-lymphangiogenic activity, said isolated isoform comprising an amino acid sequence having at least 80%, preferably at least 95%, identity to the amino acid sequence of SEQ ID NO:1, preferably is VEGF222 / NF and consists of SEQ ID NO:1.
Owner:CENT NAT DE LA RECH SCI (C N R S) +2
Anti-CD160 transmembrane isoform antibodies
PendingUS20250179175A1Polypeptide with localisation/targeting motifBiological material analysisAntigenDisease
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
Small RNA-based prognostic features and therapeutic compositions for idiopathic pulmonary fibrosis
PendingCN120513303AOrganic active ingredientsPowder deliveryIdiopathic pulmonary fibrosisBiologic marker
The present disclosure provides methods, kits, and therapeutic molecules for evaluating and treating patients with IPF and IFF subtypes. In particular, the present disclosure provides a method for diagnosing patients with IFF and IPF subtypes based on expression profiles of non-coding small RNA biomarkers. The present disclosure also provides therapeutic molecules that target the dysregulated sRNA of the expression profile. In some aspects and embodiments, the present disclosure provides miR-92a-3p isoforms and compounds that mimic the action of miR-92a-3p, or an isoform thereof, for use in therapy, including, but not limited to, therapy for IPF.
Owner:GATEHOUSE BIO INC
Anti-soluble interleukin-7 receptor antibody therapy to treat autoimmune diseases
PendingUS20260098099A1Antibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody SuppressionImmunologic disorders
Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST +1
A Method for Producing a Recombinant Allotypespecific Rabbit Monoclonal Antibody
A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a B cell from a rabbit having a B4 allotype with a 240E cell or a derivative thereof to produce a hybridoma, wherein the B cell and the hybridoma produce a monoclonal antibody; making cDNA from the hybridoma; amplifying from the cDNA a full length coding sequence for the light chain of a monoclonal antibody produced by the hybridoma using: a forward primer that hybridizes to a site in SEQ ID NO:10, and a reverse primer having a 3′ end of sequence CTARCAGTCX (SEQ ID NO:11), wherein R is A or G and X is A, AC, ACC or ACCC; and cloning the amplified sequence into an expression vector to produce a first plasmid.
Owner:ABCAM LTD
Nucleic acid agents modulating fas isoforms
The present disclosure relates to manipulation of splicing of the Fas (tumor necrosis factor (TNF) receptor superfamily, member 6) gene in non-naïve cell of the T lineage for enhanced skipping of exon 6. The manipulated non-naïve cells predominantly express a soluble form of Fas (sFas) and display reduced expression of the membranal Fas (mFas), increased cytokine secretion, increased expression of activation markers, increased cell survival, increased cytotoxicity, and / or reduced expression of exhaustion markers. The present disclosure further provides specific splicing modulatory agents comprising gene editing systems and / or splice switching antisense oligonucleotide (SSO), methods and therapeutic uses thereof.
Owner:HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
ActiveUS12540197B2Immunoglobulins against blood coagulation factorsOrganic active ingredientsAntiendomysial antibodiesAntibody conjugate
The present disclosure relates to antibodies and antibody conjugates that selectively bind to tissue factor and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies and antibody conjugates, such as therapeutic and diagnostic methods.
Owner:SUTRO BIOPHARMA INC
Isoform-selective Anti-TGF-beta antibodies and methods of use
The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2 / 3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders.
Owner:GENENTECH INC